Author: Louis Navellier and the InvestorPlace Research Staff

Any of its dips should be bought with both hands.

Each of these names are primed for low-risk, long-term growth.

Despite near-triple digit returns this year, it still has room to run.

It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

It’s offering an opportunity of significant long-term growth potential with relatively low risk.